Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Decline in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 39,700 shares, a decrease of 15.0% from the October 31st total of 46,700 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average trading volume of 23,700 shares, the days-to-cover ratio is presently 1.7 days.

Kiora Pharmaceuticals Price Performance

Shares of KPRX traded up $0.22 during trading hours on Monday, hitting $3.48. The company had a trading volume of 15,798 shares, compared to its average volume of 71,354. The business has a fifty day moving average of $3.48 and a 200-day moving average of $4.18. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.09. Equities analysts forecast that Kiora Pharmaceuticals will post 0.89 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a research report on Tuesday, November 12th.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up approximately 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.